Overview

Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
Phase:
Phase 2
Details
Lead Sponsor:
Tranzyme, Inc.